Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.

More >>
 
CCTG IND234 prostate precision medicine trial - Dr. Kim Chi

Innovative study advances personalized medicine for prostate cancer patients

CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.

More >>
 
CCTG LY16 | RELEVANCE published in New England Journal of Medicine

CCTG LY16 | RELEVANCE published in New England Journal of Medicine

The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Planned trials

ALC5

Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)

More >>

CEC7

Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease

CRC9

Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

More >>

GCC1

Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BR36

Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC

More >>

ENC1

Carboplatin & Paclitaxel with or without Pembrolizumab for Measurable Stage 3 or 4A, Stage 4B or Recurrent Endometrial Cancer

More >>

I239

CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer

More >>

LY18

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

More >>

MAC25

Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Breast Cancer

More >>

SC26

Emotion and Syptom-focused Engagement (EASE): Trial for Individuals with Acute Leukemia

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>
 

Publications

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3)

International Journal of Radiation Oncology*Biology*Physics 106: 255 - 260, 2020
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;

More >>

Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)

Clinical Lymphoma Myeloma and Leukemia 19: e272 - e273, 2019
Monteith B;Venner C;Reece D;Kew A;Lalancette M;Garland J;Shepherd L;McDonald G;Gul E;Pater J;Hay A;

More >>

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

N Engl J Med 381: 121 - 131, 2019
Davis ID;Martin AJ;Stockler MR;Begbie S;Chi KN;Chowdhury S;Coskinas X;Frydenberg M;Hague WE;Horvath LG;Joshua AM;Lawrence NJ;Marx G;McCaffrey J;McDermott R;McJannett M;North SA;Parnis F;Parulekar W;Pook DW;Reaume MN;Sandhu SK;Tan A;Tan TH;Thomson A;Tu E;Vera-Badillo F;Williams SG;Yip S;Zhang AY;Zielinski RR;Sweeney CJ;

More >>

Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)

Ann Oncol 30, 2019
Wells JC;Sidhu A;Ding K;Heng DYC;Shepherd F;Ellis PM;Bradbury PA;Jonker DJ;Moore M;Siu LL;Gelmon KA;Karapetis C;Shapiro J;Nott L;O'Callaghan CJ;Parulekar WR;Seymour LK;Smoragiewicz M;Monzon JG;

More >>

LBA18Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx

Ann Oncol 30, 2019
Sparano J;Gray RJ;Makower D;Albain K;Saphner TJ;Badve S;Wagner L;Mihalcioiu C;Desbiens C;Hayes DF;Dees EC;Geyer C;Olson J;Wood WC;Lively T;Paik S;Ellis M;Abrams JS;Sledge GW;

More >>

Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies

San Antonio Breast Cancer Symposium , 2019
Hilton J;Gelmon K;Cescon D;Tinker A;Jonker D;Goodwin R;Laurie S;Hansen A;Aparicio S;Soong J;Hagerman L;Lui H;Bedard P;Pritchard K;Tu D;Seymour L;

More >>

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Clinical Genitourinary Cancer 17: 201 - 208, 2019
Hotte SJ;Chi KN;Joshua AM;Tu D;Macfarlane RJ;Gregg RW;Ruether JD;Basappa NS;Finch D;Salim M;Winquist EW;Torri V;North S;Kollmannsberger C;Ellard SL;Eigl BJ;Tinker A;Allan AL;Beja K;Annala M;Powers J;Wyatt AW;Seymour L;

More >>